FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body

Approval is for once-daily 0.3 percent roflumilast topical foam for patients 12 years and older
Zoryve roflumilast
Photo: Arcutis Biotherapeutics
Published on
Updated on
Loading content, please wait...

Related Stories

No stories found.
logo
www.healthday.com